within Pharmacolibrary.Drugs.ATC.J;

model J05AX28
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 4.05e-06,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00332,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AX28</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bulevirtide is an entry inhibitor used for the treatment of chronic hepatitis B and D virus infection. It acts by binding to and blocking the sodium taurocholate co-transporting polypeptide (NTCP) receptor on hepatocytes, thereby preventing viral entry. Bulevirtide is approved for medical use in the European Union for chronic hepatitis D infection in adults with compensated liver disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following subcutaneous administration; population pharmacokinetic modeling.</p><h4>References</h4><ol><li><p>Zhu, V, et al., &amp; Blank, A (2023). Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers. <i>Frontiers in pharmacology</i> 14 1128547–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2023.1128547&quot;>10.3389/fphar.2023.1128547</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37089922/&quot;>https://pubmed.ncbi.nlm.nih.gov/37089922</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AX28;
